Appointment of Shanti Ekambaram as an Independent Director of the Company

28th July, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub: Disclosure under Reg 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Shanti Ekambaram as an Additional Independent Director of the Company Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the appointment of Shanti Ekambaram (DIN: 00004889) as an Additional Independent Director of the Company for a term of 3 consecutive years effective from 30th July, 2026, subject to approval of the shareholders of the Company. She is not related to any other Director of the Company. Further, we would like to inform that she is not debarred from holding the office of director by virtue of any SEBI order or any other authority. The details as required under Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, with respect to appointment are enclosed herewith as Annexure – A. Email – investorservices@torrentpharma.com The above is for your information and record. Thanking you, Yours sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: as above Email – investorservices@torrentpharma.com Annexure – A Particulars Details Reason for change viz. Appointment of Shanti Ekambaram (DIN: 00004889) as an appointment, reappointment, Additional Independent Director of the Company. resignation, removal, death or otherwise Date of appointment / 30th July, 2026 reappointment / cessation (as applicable) & term of Appointment for a term of 3 consecutive years commencing appointment/re-appointment from 30th July, 2026, subject to approval of Shareholders of the Company. Brief Profile (In case of Shanti Ekambaram, aged 63 years, is a distinguished appointment) banking business and governance leader with 39 years of financial services experience, including an exceptional 35 year tenure at Kotak Mahindra Bank where she was a part of the team that shaped the institution's transformation from a pre-IPO non-banking financial company to one of India's most respected universal banks. As Deputy Managing Director and Whole-time Director (2022-2025), she provided strategic oversight across Digital Banking, Treasury, Human Resources, Internal Audit, Vigilance, CSR/ESG, and Capital Market subsidiaries. Ms. Ekambaram's career is distinguished by her institution- building capabilities across multiple business verticals and she has a unique blend of Corporate, Retail and Digital business experience. On the India's capital markets side, she served as the CEO of Kotak Mahindra Capital Company (1997-2003), the investment banking joint venture with Goldman Sachs. She led a team that pioneered the transformation of India's equity capital markets by leading the Hughes Software IPO in 1999 – the country's first book-building transaction. This landmark achievement required intensive collaboration with SEBI, investors, and market participants to fundamentally Email – investorservices@torrentpharma.com reform IPO mechanisms, replacing archaic systems with global standards. She currently serves on the boards of Kotak Mahindra Capital Company, Kotak Securities, Havells India Limited and the Indian Institute of Management, Bangalore, where she contributes strategic direction to India's premier business education institution. Ms. Ekambaram's industry recognition underscores her standing as a preeminent business leader. She was ranked No. 1 on the Candere Hurun India Women Leaders List 2025 and named Business woman of the Year 2025 by The CEO Magazine. She has been consistently recognized by Fortune India's '50 Most Powerful Women in Business' and Business Today's 'Most Powerful Women in Indian Business' throughout her career, reflecting sustained excellence and impact. Ms. Ekambaram is a Chartered Accountant and Cost Accountant. Disclosure of relationships Shanti Ekambaram is not related to any Director of the between directors (in case of Company. appointment of Director) Email – investorservices@torrentpharma.com